Table 2 Treatment modalities and clinical courses for recurrent FSGS*
No recurrence (N = 78, 78.8%) | Recurrence (N = 21, 21.2%) | P-value | |
|---|---|---|---|
Pre-transplant treatment | 0.006 | ||
Plasmapheresis only | 23 (29.5) | 1 (4.8) | |
Plasmaphereses + rituximab | 25 (32.1) | 4 (19.0) | |
Plasmapheresis number | 2.5 ± 0.9 (N = 46) | 2.6 ± 0.9 (N = 5) | 0.90 |
Post-transplant treatment | N/A | ||
Plasmapheresis only | – | 18 (85.7) | |
Plasmaphereses + rituximab | – | 3 (14.3) | |
Time from transplantation to FSGS recurrence (days) | – | 6 (4.5–18.0) | N/A |
Post-transplant proteinuria (mg/day) | |||
Maximal proteinuria | 2785.4 ± 1961.6 | 7247.7 ± 7133.8 | < 0.001 |
Proteinuria at discharge | 319.9 ± 228.4 | 479.6 ± 411.6 | 0.10 |
Treatment result | N/A | ||
Complete remission | 8 (38.1) | ||
Partial remission | 10 (47.6) | ||
No remission | 3 (14.3) |